Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7682 results

  1. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  2. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

    In development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  3. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346

    In development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493

    Awaiting development [GID-TA11639] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049

    Awaiting development [GID-TA11635] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046

    Awaiting development [GID-TA11632] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over TSID 12047

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development